BeOne Medicines reported $1.9B in revenue (+33.8% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 4 open management expectations for this company. 4 insider sales recorded. Its latest periodic filing added 2 new risk factors.
Between November 5 and November 9, 2026, BeOne Medicines Ltd. executives conducted several stock transactions, including sales and gifts of securities. These transactions are detailed in reports filed with the Securities and Exchange Commission (SEC) during this period.
BeOne Medicines Ltd. reported third-quarter 2026 financial results, with global sales of BRUKINSA reaching $1.4 billion and free cash flow of $474 million. For shareholders, this signals strengthened financials driven by core oncology product sales, allowing the company to revise its annual guidance.
Notable transactions by executives and major shareholders from October 24 to October 30: market purchases, sales, and announced plans to sell shares. Disclosure does not indicate how an insider values a company and is not a recommendation to buy or sell.
Texas Instruments reported higher key financial metrics, Union Pacific showed increased shipping volumes, and a BeOne Medicines director sold all his shares.
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix J. Baker and Julian C. Baker each reported holding 115,457,154 (LP and GP) or 115,912,814 (Felix and Julian) shares, representing 7.8% voting power in the BeOne Medicines Ltd. class, in a filing dated September 14, 2026.
BeOne Medicines Ltd.: 12 recorded developments from 1 official source in 2026-10.
2026-09-16: Baker Bros. Advisors LP holds sole voting and dispositive power over 115,457,154 shares, representing 7.8% of the class of BeOne Medicines Ltd.Source
2026-09-16: Pursuant to the Proceeds Agreements, the Adviser funded Messrs. Krishana and Goller's exercises of the Exercised ADS Options through loans from 667 and Life Sciences.Source
2026-09-16: The amounts expended on acquiring the ADS were $566,592.72 for Exercised ADS Options held by each of Messrs. Krishana and Goller, or $1,133,185.44 in aggregate.Source
2026-09-16: The percentage of beneficial ownership for FBB3 reported herein is based on 1,478,124,405 Ordinary Shares outstanding as of July 31, 2026 as reported in the Issuer's Form 10-Q filed with the SEC on August 5, 2026 plus 399,984 Ordinary Shares issued in the form of 30,768 ADS from the exerSource
2026-09-16: Baker Bros. Advisors (GP) LLC holds sole voting and dispositive power over 115,457,154 shares, representing 7.8% of the class of BeOne Medicines Ltd.Source
2026-09-16: Entities affiliated with Julian C. Baker and Felix J. Baker each beneficially own 175,708 Ordinary Shares, 175,708 of which are held in the form of ADS.Source
2026-09-16: Felix J. Baker currently serves on the Board as a representative of the Funds.Source
2026-09-16: Julian C. Baker holds sole voting and dispositive power over 115,912,814 shares, representing 7.8% of the class of BeOne Medicines Ltd.Source
2026-09-16: Felix J. Baker holds sole voting and dispositive power over 115,912,814 shares, representing 7.8% of the class of BeOne Medicines Ltd.Source
2026-09-16: Messrs. Krishana and Goller, each of whom is a full-time employee of the Adviser, previously served on the Issuer's board of directors (the "Board") as representatives of the Funds.Source
2026-09-16: Messrs. Krishana and Goller, as agents in their capacity as former directors of the Issuer, entered into proceeds agreements (respectively, the "Krishana Proceeds Agreement" and the "Goller Proceeds Agreement" and, collectively, the "Proceeds Agreements") with the Adviser on September 14Source
2026-09-16: Messrs. Krishana and Goller have neither voting nor dispositive power over and have no direct pecuniary interest in the Exercised ADS Options or the ADS.Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Key figures
From the 10-Q for the period ended September 30, 2026, filed November 5, 2026. SEC
Latest
Earlier
Change
Revenue quarter
$1.9B
$1.4B
+33.8%
Operating income quarter
$419M
$163M
+156.7%
Net income quarter
$385M
$125M
+208.2%
Diluted EPS quarter
$0.25
$0.08
+212.5%
Operating cash flow year to date
$1.2B
$710M
+65.1%
Cash and cash equivalents balance
$5.8B
$4.5B
+27.1%
Long-term debt balance
$825M
$962M
-14.2%
Next results expected around February 4, 2027 (estimate: the quarter ending about December 30, 2026 plus the 36 days the last report took). The company announces the actual date.
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $B
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The Company expects the reversal of certain valuation allowances to occur, resulting in a material tax benefit.
Said November 5, 2026 · Period named: fourth quarter of 2026 · Source · Our article
Not yet checked against later reports.
The company provides 2026 full-year operating income guidance, forecasting GAAP operating income in the range of $1,200,000 to $1,300,000 and non-GAAP operating income in the range of $1,900,000 to $2,000,000.
Said November 5, 2026 · Period named: Full Year 2026 · Source · Our article
Not yet checked against later reports.
Total revenue guidance for full year 2026 is $6.9 billion to $7.0 billion.
Said November 5, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
The company raised its 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income to $1.2 to $1.3 billion, and non-GAAP operating income to $1.9 to $2.0 billion.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Changes in risk factors
The 10-Q filed November 5, 2026 compared with the 10-Q filed August 5, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (2)
Our employees and personnel, and third parties or vendors with whom we work, may use generative AI and other AI-enabled tools to perform their work. Employee or vendor use of unapproved or inadequately governed AI tools (including third-party tools) could create ungoverned data flows, unmonitored compliance gaps and data protection risks that are not visible until an adverse event occurs. In addition, in the ordinary course of using AI tools, users may inadvertently input or upload confidential, proprietary or other sensitive information (including trade secrets or competitively sensitive…
The GDPR in the EU and the UK, which have been incorporated into their respective laws, impose stringent requirements on the processing of personal data (especially, health and other sensitive data). These requirements encompass: (i) providing information to individuals regarding data processing activities; (ii) ensuring a legal basis or condition applies to the processing of personal data and, where applicable, obtaining consent from individuals to whom the data processing relates; (iii) responding to data subject requests; (iv) imposing requirements to notify the competent national data…
Dropped (2)
For example, in 2019, we entered into a strategic collaboration with Amgen with respect to its commercial-stage oncology products XGEVA®, BLINCYTO® and KYPROLIS® and a portfolio of clinical- and late-preclinical-stage oncology pipeline products. In 2021, we entered into a collaboration and license agreement with Novartis Pharma AG (“Novartis”), granting Novartis rights to develop, manufacture and commercialize our anti-PD-1 antibody TEVIMBRA in certain territories, but that agreement was terminated in September 2023 and we regained full, global rights to develop, manufacture and commercialize…
Additionally, our vendors may incorporate artificial intelligence tools into their offerings, and the providers of these artificial intelligence tools may not meet regulatory standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information,…
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.